Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain

References

• Strohl WR, Knight DM. Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol. 2009;20:668–14. doi:https://doi.org/10.1016/j.copbio.2009.10.012.
   PubMed Web of Science ®Google Scholar
• DiMasi JA. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. Clin Ther. 2013;35:808–18. doi:https://doi.org/10.1016/j.clinthera.2013.04.004.
   PubMed Web of Science ®Google Scholar
• Evens RP. Pharma success in product development-does biotechnology change the paradigm in product development and attrition. AAPS J. 2016;18:281–85. doi:https://doi.org/10.1208/s12248-015-9833-6.
   PubMed Web of Science ®Google Scholar
• Obrezanova O, Arnell A, de la Cuesta RG, Berthelot ME, Gallagher TR, Zurdo J, Stallwood Y. Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs. 2015;7:352–63. doi:https://doi.org/10.1080/19420862.2015.1007828.
   PubMed Web of Science ®Google Scholar
• Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016;100:3451–61. doi:https://doi.org/10.1007/s00253-016-7388-9.
   PubMed Web of Science ®Google Scholar
• van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, Aßfalg K, Baatsen P, Compernolle G, Gils A, et al. Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol. 2017;429:1244–61. doi:https://doi.org/10.1016/j.jmb.2017.03.014.
   PubMed Web of Science ®Google Scholar
• Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies–application of platform approaches. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:28–39. doi:https://doi.org/10.1016/j.jchromb.2006.09.026.
   PubMed Web of Science ®Google Scholar
• Gagnon P. Technology trends in antibody purification. J Chromatogr A. 2012;1221:57–70. doi:https://doi.org/10.1016/j.chroma.2011.10.034.
   PubMed Web of Science ®Google Scholar
• Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20:708–14. doi:https://doi.org/10.1016/j.copbio.2009.10.006.
   PubMed Web of Science ®Google Scholar
• Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185:129–88. doi:https://doi.org/10.1016/S0378-5173(99)00152-0.
   PubMed Web of Science ®Google Scholar
• Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93:1390–402. doi:https://doi.org/10.1002/jps.20079.
   PubMed Web of Science ®Google Scholar
• Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ, et al. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. MAbs. 2015;7:212–30. doi:https://doi.org/10.4161/19420862.2014.985504.
   PubMed Web of Science ®Google Scholar
• Kumar S, Plotnikov NV, Rouse JC, Singh SK. Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics. J Pharm Pharmacol. 2018;70:595–608. doi:https://doi.org/10.1111/jphp.12700.
   PubMed Web of Science ®Google Scholar
• Popovic B, Gibson S, Senussi T, Carmen S, Kidd S, Slidel T, Strickland I, Jianqing X, Spooner J, Lewis A, et al. Engineering the expression of an anti-interleukin-13 antibody through rational design and mutagenesis.. Protein Eng Des Sel. 2017;30(4):303–11. doi:https://doi.org/10.1093/protein/gzx001.
   PubMed Web of Science ®Google Scholar
• Shan L, Mody N, Sormani P, Rosenthal KL, Damschroder MM, Esfandiary R. Developability assessment of engineered monoclonal antibody variants with a complex self-association behavior using complementary analytical and in silico tools. Mol Pharm. 2018;15:5697–710. doi:https://doi.org/10.1021/acs.molpharmaceut.8b00867.
   PubMed Web of Science ®Google Scholar
• Kumar S, Roffi K, Tomar DS, Cirelli D, Luksha N, Meyer D, Mitchell J, Allen MJ, Li L. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity. Protein Eng Des Sel. 2018;31(7–8):313–25. doi:https://doi.org/10.1093/protein/gzy020.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Li L, Broulidakis MP, Luksha NG, Burns CT, Singh SK, Kumar S. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. MAbs. 2017;9(3):476–89. doi:https://doi.org/10.1080/19420862.2017.1285479.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111(52):18601–06. doi:https://doi.org/10.1073/pnas.1421779112.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PW, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6(1):38644. doi:https://doi.org/10.1038/srep38644.
   PubMed Web of Science ®Google Scholar
• Tartaglia GG, Vendruscolo M. The Zyggregator method for predicting protein aggregation propensities. Chem Soc Rev. 2008;37:1395–401. doi:https://doi.org/10.1039/b706784b.
   PubMed Web of Science ®Google Scholar
• Louros N, Konstantoulea K, De Vleeschouwer M, Ramakers M, Schymkowitz J, Rousseau F. WALTZ-DB 2.0: an updated database containing structural information of experimentally determined amyloid-forming peptides. Nucleic Acids Res. 2019;48(D1):D389–393.
   Web of Science ®Google Scholar
• Maurer-Stroh S, Debulpaep M, Kuemmerer N, Lopez de la Paz M, Martins IC, Reumers J, Morris KL, Copland A, Serpell L, Serrano L, et al. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods. 2010;7(3):237–42. doi:https://doi.org/10.1038/nmeth.1432.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Sievers SA, Karanicolas J, Ivanova MI, Baker D, Eisenberg D. The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A. 2006;103:4074–78. doi:https://doi.org/10.1073/pnas.0511295103.
   PubMed Web of Science ®Google Scholar
• Rawat P, Kumar S, Michael Gromiha M. An in-silico method for identifying aggregation rate enhancer and mitigator mutations in proteins. Int J Biol Macromol. 2018;118:1157–67. doi:https://doi.org/10.1016/j.ijbiomac.2018.06.102.
   PubMed Web of Science ®Google Scholar
• Sanchez de Groot N, Pallares I, Aviles FX, Vendrell J, Ventura S. Prediction of “hot spots” of aggregation in disease-linked polypeptides. BMC Struct Biol. 2005;5:18. doi:https://doi.org/10.1186/1472-6807-5-18.
   PubMed Web of Science ®Google Scholar
• Trovato A, Seno F, Tosatto SC. The PASTA server for protein aggregation prediction. Protein Eng Des Sel. 2007;20:521–23. doi:https://doi.org/10.1093/protein/gzm042.
   PubMed Web of Science ®Google Scholar
• Zibaee S, Makin OS, Goedert M, Serpell LC. A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. Protein Sci. 2007;16:906–18. doi:https://doi.org/10.1110/ps.062624507.
   PubMed Web of Science ®Google Scholar
• Frousios KK, Iconomidou VA, Karletidi CM, Hamodrakas SJ. Amyloidogenic determinants are usually not buried. BMC Struct Biol. 2009;9:44. doi:https://doi.org/10.1186/1472-6807-9-44.
   PubMed Web of Science ®Google Scholar
• Tian J, Wu N, Guo J, Fan Y. Prediction of amyloid fibril-forming segments based on a support vector machine. BMC Bioinformatics. 2009;10(Suppl 1):S45. doi:https://doi.org/10.1186/1471-2105-10-S1-S45.
   PubMed Web of Science ®Google Scholar
• Galzitskaya OV, Garbuzynskiy SO, Lobanov MY. Prediction of amyloidogenic and disordered regions in protein chains. PLoS Comput Biol. 2006;2:e177. doi:https://doi.org/10.1371/journal.pcbi.0020177.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106:11937–42. doi:https://doi.org/10.1073/pnas.0904191106.
   PubMed Web of Science ®Google Scholar
• Van Durme J, De Baets G, Van Der Kant R, Ramakers M, Ganesan A, Wilkinson H, Gallardo R, Rousseau F, Schymkowitz J. Solubis: a webserver to reduce protein aggregation through mutation. Protein Eng Des Sel. 2016;29:285–89. doi:https://doi.org/10.1093/protein/gzw019.
   PubMed Web of Science ®Google Scholar
• Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol. 2004;22:1302–06. doi:https://doi.org/10.1038/nbt1012.
   PubMed Web of Science ®Google Scholar
• Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382–8. doi:https://doi.org/10.1093/nar/gki387.
   PubMed Web of Science ®Google Scholar
• Davies SL, Lovelady CS, Grainger RK, Racher AJ, Young RJ, James DC. Functional heterogeneity and heritability in CHO cell populations. Biotechnol Bioeng. 2013;110:260–74. doi:https://doi.org/10.1002/bit.24621.
   PubMed Web of Science ®Google Scholar
• Mason M, Sweeney B, Cain K, Stephens P, Sharfstein ST. Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells. Biotechnol Prog. 2012;28:846–55. doi:https://doi.org/10.1002/btpr.1542.
   PubMed Web of Science ®Google Scholar
• Mathias S, Wippermann A, Raab N, Zeh N, Handrick R, Gorr I, Schulz P, Fischer S, Gamer M, Otte K. Unravelling what makes a monoclonal antibody difficult-to-express: from intracellular accumulation to incomplete folding and degradation via ERAD. Biotechnol Bioeng. 2019;117:5–16. doi:https://doi.org/10.1002/bit.27196.
   PubMed Web of Science ®Google Scholar
• Gronemeyer P, Ditz R, Strube J. Trends in upstream and downstream process development for antibody manufacturing. Bioeng (Basel). 2014;1:188–212. doi:https://doi.org/10.3390/bioengineering1040188.
   PubMedGoogle Scholar
• Paborji M, Pochopin NL, Coppola WP, Bogardus JB. Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm Res. 1994;11:764–71. doi:https://doi.org/10.1023/A:1018948901599.
   PubMed Web of Science ®Google Scholar
• Zheng JY, Janis LJ. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm. 2006;308(1–2):46–51. doi:https://doi.org/10.1016/j.ijpharm.2005.10.024.
   PubMed Web of Science ®Google Scholar
• Garidel P, Karow AR, Blech M. Orthogonal spectroscopic techniques for the early developability assessment of therapeutic protein candidates. Spectrosc Eur. 2014;26:9–13.
   Google Scholar
• Kommanaboyina B, Rhodes CT. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm. 1999;25:857–68. doi:https://doi.org/10.1081/DDC-100102246.
   PubMed Web of Science ®Google Scholar
• Pokharana M, Vaishnav R, Goyal AAS. Stability testing guidelines of pharmaceutical products. J Drug Delivery Ther. 2018;8:169–75. doi:https://doi.org/10.22270/jddt.v8i2.1564.
   Google Scholar
• Sukumar M, Doyle BL, Combs JL, Pekar AH. Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm Res. 2004;21:1087–93. doi:https://doi.org/10.1023/B:PHAM.0000032993.98705.73.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Kumar S, Singh SK, Goswami S, Li L. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. MAbs. 2016;8:216–28. doi:https://doi.org/10.1080/19420862.2015.1128606.
   PubMed Web of Science ®Google Scholar
• Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625–31. doi:https://doi.org/10.1074/jbc.M507783200.
   PubMed Web of Science ®Google Scholar
• Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm. 2012;9:791–802. doi:https://doi.org/10.1021/mp200566k.
   PubMed Web of Science ®Google Scholar
• Sormanni P, Aprile FA, Vendruscolo M. Third generation antibody discovery methods: in silico rational design. Chem Soc Rev. 2018;47:9137–57. doi:https://doi.org/10.1039/C8CS00523K.
   PubMed Web of Science ®Google Scholar
• Pybus LP, James DC, Dean G, Slidel T, Hardman C, Smith A, Daramola O, Field R. Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domain. Biotechnol Prog. 2014;30:188–97. doi:https://doi.org/10.1002/btpr.1839.
   PubMed Web of Science ®Google Scholar
• Bentley KJ, Gewert R, Harris WJ. Differential efficiency of expression of humanized antibodies in transient transfected mammalian cells. Hybridoma. 1998;17:559–67. doi:https://doi.org/10.1089/hyb.1998.17.559.
   PubMedGoogle Scholar
• Hasegawa H, Hsu A, Tinberg CE, Siegler KE, Nazarian AA, Tsai MM. Single amino acid substitution in LC-CDR1 induces Russell body phenotype that attenuates cellular protein synthesis through eIF2alpha phosphorylation and thereby downregulates IgG secretion despite operational secretory pathway traffic. MAbs. 2017;9:854–73. doi:https://doi.org/10.1080/19420862.2017.1314875.
   PubMed Web of Science ®Google Scholar
• Dwek RA. Biological importance of glycosylation. Dev Biol Stand. 1998;96:43–47.
   PubMedGoogle Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–34. doi:https://doi.org/10.1093/glycob/cwv065.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21:949–59. doi:https://doi.org/10.1093/glycob/cwr027.
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan J-P, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. MAbs. 2012;4(4):475–87. doi:https://doi.org/10.4161/mabs.20737.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–604. doi:https://doi.org/10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47. doi:https://doi.org/10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Levy NE, Valente KN, Choe LH, Lee KH, Lenhoff AM. Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing. Biotechnol Bioeng. 2014;111:904–12. doi:https://doi.org/10.1002/bit.25158.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Blech M, Presser I, Garidel P. Polysorbate degradation in biotherapeutic formulations: identification and discussion of current root causes. Int J Pharm. 2018;552:422–36. doi:https://doi.org/10.1016/j.ijpharm.2018.10.008.
   PubMed Web of Science ®Google Scholar
• Goswami S, Wang W, Arakawa T, Ohtake S. Developments and Challenges for mAb-Based Therapeutics. Antibodies. 2013;2:452–500. doi:https://doi.org/10.3390/antib2030452.
   Google Scholar
• Garidel P, Kuhn AB, Schafer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353–60. doi:https://doi.org/10.1016/j.ejpb.2017.06.029.
   PubMed Web of Science ®Google Scholar
• Yang Y, Velayudhan A, Thornhill NF, Farid SS. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations. Biotechnol Bioeng. 2017;114:2043–56. doi:https://doi.org/10.1002/bit.26329.
   PubMed Web of Science ®Google Scholar
• Zurdo J. Developability assessment as an early de-risking tool for biopharmaceutical development. Pharm Bioprocess. 2013;1:29–50. doi:https://doi.org/10.4155/pbp.13.3.
   Google Scholar
• van der Kant R, Bauer J, Karow-Zwick AR, Kube S, Garidel P, Blech M, Rousseau F, Schymkowitz J Adaption of human antibody λ and κ light chain architectures to CDR repertoires. PEDS. 2019;32:109–127. doi:https://doi.org/10.1093/protein/gzz012.
   Google Scholar
• Krieger E, Vriend G. Models@Home: distributed computing in bioinformatics using a screensaver based approach. Bioinformatics. 2002;18:315–18.
   PubMed Web of Science ®Google Scholar
• Siekierska A, De Baets G, Reumers J, Gallardo R, Rudyak S, Broersen K, Couceiro J, Van Durme J, Schymkowitz J, Rousseau F. alpha-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem. 2012;287:28386–97. doi:https://doi.org/10.1074/jbc.M112.351056.
   PubMed Web of Science ®Google Scholar
• Bergemann K, Eckermann C, Garidel P, Grammatikos S, Jacobi A, Kaufmann H, Kempken R, Pisch‐Heberle S. Production and downstream processing. In: Dübel S, editor. Handbook of therapeutic antibodies. Wiley-VCH. 2008. p. 199–237.
   Google Scholar
• Jacobi A, Enenkel B, Garidel P, Eckermann C, Knappenberger M, Presser I, Kaufmann H. Process development and manufacturing of therapeutic antibodies. In: Dübel S, editor. Handbook of therapeutic antibodies. Wiley-VCH. 2014. p. 601–64.
   Google Scholar
• Karow AR, Bahrenburg S, Garidel P. Buffer capacity of biologics–from buffer salts to buffering by antibodies. Biotechnol Prog. 2013;29:480–92. doi:https://doi.org/10.1002/btpr.1682.
   PubMed Web of Science ®Google Scholar
• Zydney AL, Kurlyel R. Protein concentration and buffer exchange using ultrafiltration. In: Desai MA editor. Downstream processing of proteins. Methods in biotechnology. Totowa (NJ): Humana Press; 2000. p. 9.
   Google Scholar
• Garidel P, Herre A, Kliche W. Microscopic methods for particle characterization in protein pharmaceuticals. In: Mahler HC, Jiskoot W, editors. Analysis of aggregates and particles in protein pharmaceuticals. New Jersey: John Wiley & Sons; 2012. p. 269–302. doi:https://doi.org/10.1002/9781118150573.ch12
   Google Scholar
• Weinbuch D, Zolls S, Wiggenhorn M, Friess W, Winter G, Jiskoot W, Hawe A. Micro-flow imaging and resonant mass measurement (Archimedes)–complementary methods to quantitatively differentiate protein particles and silicone oil droplets. J Pharm Sci. 2013;102:2152–65. doi:https://doi.org/10.1002/jps.23552.
   PubMed Web of Science ®Google Scholar